{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:49:55Z","timestamp":1792669795197,"version":"4.5.0"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lassa fever (LF) is an acute viral hemorrhagic illness endemic to West Africa, with no licensed vaccines or targeted treatments available, highlighting a critical gap in global health preparedness. T cell-mediated immunity plays a central role in viral control and survival. Synthetic DNA vaccines offer a promising strategy to induce both humoral and cellular immunity against LF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Phase 1b, randomized, double-blind, placebo-controlled trial was conducted to assess the safety, tolerability, and immunogenicity of INO-4500, a DNA vaccine encoding the Lassa virus (Josiah strain) glycoprotein precursor (GPC). A total of 220 healthy adults were randomized to receive either 1 mg or 2 mg of INO-4500 (intervention), or placebo, administered intradermally (ID) followed by electroporation (EP) at Day 0 and Week 4. Safety was evaluated through Week 48. Primary immunogenicity endpoints included humoral and cellular immune responses at multiple timepoints post-vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>INO-4500 was well tolerated, with no Grade 3 or higher treatment-emergent adverse events (TEAEs) deemed to be related to the intervention; 88.6% of all TEAEs were Grade 1. No cases of attributable hearing loss were reported. INO-4500 groups demonstrated statistically significant increases in Lassa virus GPC-specific binding antibodies at Weeks 6 and 12 compared to placebo, with the 2 mg group eliciting the strongest responses. T cell responses remained elevated above baseline through Week 48 in both INO-4500 groups, indicating durable cellular immunity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DNA vaccine INO-4500 was well tolerated and elicited durable humoral and cellular immune responses in healthy adults. These findings support further clinical development of INO-4500 as a potential preventive vaccine to reduce LF-associated morbidity and mortality in endemic regions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/clinicaltrials.gov<\/jats:uri>\n                      , identifier NCT04093076\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1658549","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:16:38Z","timestamp":1761293798000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults"],"prefix":"10.3389","volume":"16","author":[{"given":"Kwadwo Ansah","family":"Koram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen A.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventure","family":"Orizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idania","family":"Marrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShuPing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate E.","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwadwo Asamoah","family":"Kusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Kyei-Baafour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebenezer Addo","family":"Ofori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Pobee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Adu-Amankwah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Amoakoh-Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Brown","family":"Amoakoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Abuaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edem","family":"Badji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ntiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Quaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Reuschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Liebowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent M.","family":"Humeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2019.08.002","article-title":"Lassa fever: epidemiology, clinical features, diagnosis, management and prevention","volume":"33","author":"Asogun","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2019.07.006","article-title":"A Review of Lassa Fever Vaccine Candidates","volume":"37","author":"Salami","year":"2019","journal-title":"Curr Opin Virol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/v16020266","article-title":"The importance of lassa fever and its disease management in west africa","volume":"16","author":"Reyna","year":"2024","journal-title":"Viruses"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03232-y","article-title":"Health and economic impacts of lassa vaccination campaigns in west africa","volume":"30","author":"Smith","year":"2024","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12985-024-02585-7","article-title":"Current perspectives on vaccines and therapeutics for lassa fever","volume":"21","author":"Warner","year":"2024","journal-title":"Virol J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2019.03.008","article-title":"Vaccine platforms for the prevention of lassa fever","volume":"215","author":"Purushotham","year":"2019","journal-title":"Immunol Lett"},{"key":"B7","unstructured":"Lassa Fever\n          \n          \n          \n          2025"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/traa011","article-title":"Lassa fever in pregnancy: A systematic review and meta-analysis","volume":"114","author":"Kayem","year":"2020","journal-title":"Trans R Soc Trop Med Hygiene"},{"key":"B9","unstructured":"R&D Blueprint. Lassa Fever\n          \n          \n          \n          2025"},{"key":"B10","unstructured":"Clinicaltrials.Gov. A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV\u0394G-LASV-GPC Vaccine in Adults in Good General Heath\n          \n          \n          \n          2024"},{"key":"B11","unstructured":"Clinicaltrials.Gov. A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa\n          \n          \n          \n          2024"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.13876","article-title":"Lassa Fever vaccine candidates: A scoping review of vaccine clinical trials","volume":"28","author":"Sulis","year":"2023","journal-title":"Trop Med Int Health"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00048-X","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-vectored lassa fever vaccine: A randomised, placebo-controlled, first-in-human trial","volume":"401","author":"Tschismarov","year":"2023","journal-title":"Lancet"},{"key":"B14","unstructured":"Vaccine Technology\n          \n          \n          \n          2025"},{"key":"B15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s43856-024-00684-8","article-title":"The DNA-based lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal lassa fever","volume":"4","author":"Andrade","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0010882","DOI":"10.1371\/journal.pntd.0010882","article-title":"Expansion of CD8+ T cell population in lassa virus survivors with low T cell precursor frequency reveals durable immune response in most survivors","volume":"16","author":"LaVergne","year":"2022","journal-title":"PloS Negl Trop Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1008352","DOI":"10.1371\/journal.ppat.1008352","article-title":"High crossreactivity of human T cell responses between lassa virus lineages","volume":"16","author":"Sullivan","year":"2020","journal-title":"PloS Pathog"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01948-08","article-title":"Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys","volume":"83","author":"Baize","year":"2009","journal-title":"J Virol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.74.5.2186-2192.2000","article-title":"Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the lassa virus nucleoprotein","volume":"74","author":"ter Meulen","year":"2000","journal-title":"J Virol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant lassa\u2013rabies vaccine are critical for protection against lassa fever","volume":"9","author":"Abreu-Mota","year":"2018","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1616499","article-title":"Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccines immunotherapeutics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41541-018-0049-5","article-title":"Baseline mapping of lassa fever virology, epidemiology and vaccine research and development","volume":"3","author":"Hallam","year":"2018","journal-title":"NPJ Vaccines"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3390\/vaccines10101668","article-title":"Understanding immune responses to lassa virus infection and to its candidate vaccines","volume":"10","author":"Murphy","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.74.15.6777-6783.2000","article-title":"Effective vaccine for lassa fever","volume":"74","author":"Fisher-Hoch","year":"2000","journal-title":"J Virol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1038\/s41467-023-41376-6","article-title":"A Lassa Virus mRNA Vaccine Confers Protection but Does Not Require Neutralizing Antibody in a Guinea Pig Model of Infection","volume":"14","author":"Ronk","year":"2023","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/vaccines7040138","article-title":"Differential immune responses to hemorrhagic fever-causing arenaviruses","volume":"7","author":"Mantlo","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/v4112766","article-title":"Immune responses and lassa virus infection","volume":"4","author":"Russier","year":"2012","journal-title":"Viruses"},{"key":"B28","doi-asserted-by":"publisher","first-page":"F1000 Faculty Rev-134","DOI":"10.12688\/f1000research.16989.1","article-title":"Lassa virus diversity and feasibility for universal prophylactic vaccine","volume":"8","author":"Lukashevich","year":"2019","journal-title":"F1000Research"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1356500","article-title":"A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against lassa fever","volume":"13","author":"Cashman","year":"2017","journal-title":"Hum Vaccines immunotherapeutics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"6992","DOI":"10.1128\/jvi.74.15.6992-7004.2000","article-title":"Genetic diversity among lassa virus strains","volume":"74","author":"Bowen","year":"2000","journal-title":"J Virol"},{"key":"B31","unstructured":"Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials\n          \n          \n          \n          2025"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.08.021","article-title":"Lassa fever induced hearing loss: the neglected disability of hemorrhagic fever","volume":"100","author":"Ficenec","year":"2020","journal-title":"Int J Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126525","article-title":"Report of a SPEAC webinar 22 september 2023: sensorineural hearing loss, lassa virus disease and vaccines","volume":"43","author":"Reed","year":"2025","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.05.019","article-title":"Sensorineural hearing loss (SNHL) as an adverse event following immunization (AEFI): case definition & Guidelines for data collection, analysis, and presentation of immunization safety data","volume":"38","author":"Liu","year":"2020","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2290834","article-title":"Spatio-temporal spread of lassa virus and a new rodent host in the mano river union area, west africa","volume":"13","author":"Bangura","year":"2024","journal-title":"Emerg Microbes Infect"},{"key":"B36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12978-025-02008-y","article-title":"Safety, immunogenicity, efficacy, and effectiveness of lassa fever vaccines in pregnant persons, children, and adolescents: A protocol for a living systematic review and meta-analysis","volume":"22","author":"Ballivian","year":"2025","journal-title":"Reprod Health"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00229-9","article-title":"Lassa fever research priorities: towards effective medical countermeasures by the end of the decade","volume":"24","author":"Moore","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B38","unstructured":"WHO Target Product Profile for Lassa Virus Vaccine\n          \n          \n          \n          2017"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.02.044","article-title":"Lassa fever vaccine use cases and demand: perspectives from select west african experts","volume":"42","author":"Kabor\u00e9","year":"2024","journal-title":"Vaccine"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104928","article-title":"Lassa virus antigen distribution and inflammation in the ear of infected strain 13\/N Guinea pigs","volume":"183","author":"Huynh","year":"2020","journal-title":"Antiviral Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2448405","article-title":"Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial","volume":"21","author":"Jia","year":"2025","journal-title":"Hum Vaccines immunotherapeutics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.urolonc.2013.09.014","article-title":"Preclinical and clinical development of DNA vaccines for prostate cancer","volume":"34","author":"Colluru","year":"2016","journal-title":"Urol Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac016","article-title":"SARS-coV-2 DNA vaccine INO-4800 induces durable immune responses capable of being boosted in a phase 1 open-label trial","volume":"225","author":"Kraynyak","year":"2022","journal-title":"J Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/s41467-025-56729-6","article-title":"DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1\/2 study assessing efficacy, safety, and immunogenicity of INO-3107","volume":"16","author":"Morrow","year":"2025","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz132","article-title":"Intradermal syncon(R) ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers","volume":"220","author":"Tebas","year":"2019","journal-title":"J Infect Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-coV-2: A preliminary report of an open-label, phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108906","article-title":"Adverse events following COVID-19 vaccination: A systematic review and meta-analysis","volume":"109","author":"Kouhpayeh","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/v4102031","article-title":"Pathogenesis of lassa fever","volume":"4","author":"Yun","year":"2012","journal-title":"Viruses"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(85)90388-8","article-title":"Endemic lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization","volume":"79","author":"Jahrling","year":"1985","journal-title":"Trans R Soc Trop Med Hygiene"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-middle east respiratory syndrome coronavirus DNA vaccine: A phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix201","article-title":"A case of human lassa virus infection with robust acute T-cell activation and long-term virus-specific T-cell responses","volume":"215","author":"McElroy","year":"2017","journal-title":"J Infect Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e00153-20","DOI":"10.1128\/jvi.00153-20","article-title":"Identification of common CD8+ T cell epitopes from lassa fever survivors in Nigeria and Sierra Leone","volume":"94","author":"Sakabe","year":"2020","journal-title":"J Virol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1382780","article-title":"DNA vaccines elicit durable protective immunity against individual or simultaneous infections with lassa and ebola viruses in Guinea pigs","volume":"13","author":"Cashman","year":"2017","journal-title":"Hum Vaccines immunotherapeutics"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e146082","DOI":"10.1172\/jci.insight.146082","article-title":"Intradermal delivery of a synthetic DNA vaccine protects macaques from middle east respiratory syndrome coronavirus","volume":"6","author":"Patel","year":"2021","journal-title":"JCI Insight"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.10.057","article-title":"Production of pharmaceutical-grade plasmids at high concentration and high supercoiled percentage","volume":"28","author":"Cai","year":"2010","journal-title":"Vaccine"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.01.006","article-title":"DNA vaccines: prime time is now","volume":"65","author":"Gary","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3390\/vaccines11061016","article-title":"DNA vaccines for epidemic preparedness: SARS-coV-2 and beyond","volume":"11","author":"Maslow","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines1030225","article-title":"Vector design for improved DNA vaccine efficacy, safety and production","volume":"1","author":"Williams","year":"2013","journal-title":"Vaccines (Basel)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat Rev Genet"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(24)00210-x","article-title":"Urgent considerations for booster vaccination strategies against ebola virus disease","volume":"24","author":"Adriaensen","year":"2024","journal-title":"Lancet Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1658549\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:16:43Z","timestamp":1761293803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1658549\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2025.1658549"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1658549","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"article-number":"1658549"}}